Article Listing - ESBATech raises $22M in extended series B round
PRICE SET FOR ELF AQUITAIN FLOAT
23 March 1992
The French goverment has set the price for the sale of a 2.3% stake in Elf Aquitaine, which controls the...
PHARMA ECONOMICS 1942/1992 PERSPECTIVE
23 March 1992
Enoch Powell, who was Minister of Health in the UK back in the 60s, and responsible for what would now...
FROM A RESEARCH-LED TO A MARKET-DRIVEN FIRM
23 March 1992
The task ofpharmaceutical industry management is to achieve the best possible balance between the constant pull of the market...
ESTRAPAK FOR OSTEOPOROSIS IN UK
23 March 1992
Ciba-Geigy's transdermal hormone replacement therapy Estrapak 50, which combines an estrogen patch and progestogen tablets for endometrial protection, is now...
FORTHCOMING MEETINGS
23 March 1992
The following Rostrum-organized meetings of potential interest to pharmaceutical industry personnel will be held at The Royal Society of Medicine,...
USER FEES URGED IN ONTARIO
23 March 1992
In Canada, the drug benefit program operated by the province of Ontario should introduce "modest" user fees to encourage patients,...
STRONGER WARNINGS ON ACE INHIBITORS
23 March 1992
At the request of the US Food and Drug Administration, six manufacturers of ACE inhibitors are putting stronger warning labels...
STOCK MARKET COMMENTARY: NEW YORK
23 March 1992
NEW YORK: see-sawed through the reporting week, first down on caution ahead of economic data and interest rate concerns and...
STOCK MARKET COMMENTARY: TOKYO
23 March 1992
TOKYO: stocks fell below the psychologically important 20,000 yen level last week to a five-year low. The decline was a...
STOCK MARKET COMMENTARY: EUROPE
23 March 1992
EUROPE: stock markets were nearly all down, with the lead coming from New York and Tokyo. On the FRANKFURT exchange,...
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
